Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2019 Apr 8;18(6):1115–1126. doi: 10.1158/1535-7163.MCT-18-0743

Table 1.

Characterization of PDX models

PDX PATIENT tumor source (34,35)1 PATIENT clinical treatments (34,35)2 HER2 IHC-score ER Status3 BCL-2 H-score4 BCL-XL H-score4
PDX12 post-T× PE cape; vino; trastuzumab; lapatinib 1+ − 0 97
PDX8 post-T× PE 5-FU; cape 2+ − 0 183
BCM-3963 pre-T× PT NONE 3+ − 0 110
BCM-4888 post-T× PT cyclo; doxo; GSI 2+ + 13 102
BCM-3613 post-T× PE cyclo; doxo; pacl; trastuzumab; lapatinib; GSI; doce; others 3+ − 0 117
1

T×, treatment; PE, pleural effusion; PT, primary breast tumor

2

cape, capecitabine; vino, vinorelbine; 5-FU, 5-fluorouracil; cyclo, cyclophosamide; doxo, doxorubicin; GSI, gamma secretase inhibitor; pacl, paclitaxel; doce, docetaxel

3

ER -positive (+) or -negative (−) as previously described (34,35)

4

H-score represents the average of 3–5 tumors per PDX